KR20130052386A - Bacterial synthesized citrus cellolose for wound healing and dressing materials containing the same - Google Patents

Bacterial synthesized citrus cellolose for wound healing and dressing materials containing the same Download PDF

Info

Publication number
KR20130052386A
KR20130052386A KR1020110117794A KR20110117794A KR20130052386A KR 20130052386 A KR20130052386 A KR 20130052386A KR 1020110117794 A KR1020110117794 A KR 1020110117794A KR 20110117794 A KR20110117794 A KR 20110117794A KR 20130052386 A KR20130052386 A KR 20130052386A
Authority
KR
South Korea
Prior art keywords
wound
wound healing
citrus
dressing
cellulose gel
Prior art date
Application number
KR1020110117794A
Other languages
Korean (ko)
Other versions
KR101365065B1 (en
Inventor
김미선
박대환
김성호
김인호
최영훈
이선이
Original Assignee
대구가톨릭대학교산학협력단
대한민국(농촌진흥청장)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 대구가톨릭대학교산학협력단, 대한민국(농촌진흥청장) filed Critical 대구가톨릭대학교산학협력단
Priority to KR1020110117794A priority Critical patent/KR101365065B1/en
Publication of KR20130052386A publication Critical patent/KR20130052386A/en
Application granted granted Critical
Publication of KR101365065B1 publication Critical patent/KR101365065B1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/75Rutaceae (Rue family)
    • A61K36/752Citrus, e.g. lime, orange or lemon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • C12N1/205Bacterial isolates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/02Acetobacter

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)

Abstract

PURPOSE: A citrus-derived bacteria cellulose gel for wound healing and a dressing containing the same are provided to reduce initial inflammation reaction, to promote contraction through accumulation of extracellular matrix, and to enhance wound healing effects. CONSTITUTION: A cellulose gel for wound healing is prepared by extracting citrus using Gluconacetobacter. A dressing for wound healing contains the cellulose gel as an active ingredient. The dressing is a hydrocolloid or wet foam type. The dressing reduces initial inflammation reaction, promotes contraction through accumulation of extracellular matrix, and has wound healing effects. [Reference numerals] (AA) Wound area(%); (BB) Elapsed days after procedure(days)

Description

창상 치료용 감귤 유래 박테리아 셀룰로오스 겔 및 이를 함유하는 드레싱 제재 {Bacterial synthesized citrus cellolose for wound healing and dressing materials containing the same}Citrus-derived bacterial cellulose gel for wound healing and dressing agent containing the same {Bacterial synthesized citrus cellolose for wound healing and dressing materials containing the same}

본 발명은 창상 치료용 감귤 유래 박테리아 셀룰로오스 겔 및 이를 함유하는 드레싱 제재에 관한 것으로, 보다 구체적으로는 글루콘아세토박터속 균주를 이용하여 감귤에서 추출한 셀룰로오스 겔의 창상 치료 효과를 밝히고, 이를 함유하는 드레싱 제재를 제공하기 위한 것이다.
The present invention relates to a tangerine-derived bacterial cellulose gel for wound treatment and a dressing preparation containing the same, and more specifically, to reveal the wound healing effect of a cellulose gel extracted from citrus fruits using a gluconacetobacter strain, and a dressing containing the same. To provide sanctions.

창상의 치유과정은 시간 순으로 염증단계, 상피화 단계, 증식단계 그리고 성숙단계의 네 단계로 구분될 수 있으나 각 단계는 명확한 구분 없이 어느 정도 중첩되면서 연속적으로 진행된다. 창상치유의 네 단계 중에서 임상적으로 가장 중요한 것이 바로 염증단계이다. 이 단계에서 파괴된 조직부유물 및 괴사된 조직이 급성 및 만성 염증세포에 의해 제거 또는 함입되어야 다음 단계로 이행할 수 있으며, 이 단계가 오래 지속되면 다음 창상 치유과정이 지연된다. 따라서 대부분의 창상치유에 쓰이는 소재들 또는 약품들도 이 염증단계에 노출된 창상의 지혈을 돕고, 유해한 외부 환경으로부터 창상을 차단하고 보호하며, 미생물의 감염을 예방하고 다음 창상치유 단계로 빨리 치유가 진행될 수 있도록 하는 데에 그 목적을 두고 있다. 또한 이러한 소재들은 염증기 이후의 증식 단계에도 작용을 하여 섬유모세포를 증식시키고 섬유모세포의 이동을 활성화하고 콜라겐 합성을 증가시켜 궁극적으로 창상 수축을 통하여 창상 치유를 촉진시킨다.The healing process of the wound can be divided into four stages: inflammatory, epithelial, proliferative and mature stages, but each stage is continuously overlapped to some extent without clear distinction. Of the four stages of wound healing, the most clinically important is the inflammatory stage. At this stage, destroyed tissue debris and necrotic tissue must be removed or incorporated by acute and chronic inflammatory cells to move on to the next stage, which lasts longer to delay the next wound healing process. Therefore, most of the materials or medicines used for wound healing help to hemostasis of wounds exposed to this inflammatory stage, block and protect the wound from harmful external environment, prevent microbial infection and heal quickly to the next wound healing stage. Its purpose is to make it progress. These materials also act in the proliferative phase after the inflammatory phase, which proliferates fibroblasts, activates the migration of fibroblasts, increases collagen synthesis, and ultimately promotes wound healing through wound contraction.

드레싱 제재는 물리적 및 기계적 내구성이 높아 상처에 부착되어 상처보호 및 감염을 방지하고, 우수한 생체 친화성을 가지며 재료 자체가 약리효과를 부수적으로 발현할 수 있어야 한다. 그 동안 창상 드레싱 제재로서 이용될 수 있는 소재는 생체조직에 대하여 거부반응이 최소화되는 소재, 즉 생체조직에 대하여 불활성을 갖는 합성고분자 부류 등으로 극히 한정되어 왔다. 천연소재들의 경우 합성소재들에 비하여 인체친화성이 우수하지만, 인체에 대한 거부반응이 완전히 배제될 수 없을 뿐만 아니라 합성고분자 소재들에 비해 물리적 특성과 기계적 강도 등이 낮아 사용에 한계점이 있다. 특히 천연고분자 소재는 주변 환경의 변화에 따라 변성될 가능성이 크고 특성이 균일하게 유지될 수 없다는 점도 단점 중 하나로 지적되고 있다. The dressing material must have high physical and mechanical durability to adhere to the wound to prevent wound protection and infection, have good biocompatibility, and the material itself can additionally exhibit pharmacological effects. In the meantime, materials that can be used as wound dressing materials have been extremely limited to materials that minimize rejection of biological tissues, that is, synthetic polymer classes having inertness to biological tissues. Natural materials have better human friendliness than synthetic materials, but rejection of the human body can not be completely excluded, and physical properties and mechanical strength are lower than those of synthetic polymer materials. In particular, it is pointed out that the natural polymer material is likely to be denatured according to the change of the surrounding environment, and the characteristics cannot be maintained uniformly.

셀룰로오스(cellulose)는 고등식물의 세포벽을 구성하는 주성분으로 자연계에 존재하는 풍부한 생체 물질 자원이다. 식물 셀룰로오스의 경우 펙틴(pectin), 헤미셀룰로오스(hemicelluloses), 리그닌(lignin) 등의 다당류와 혼합하여 헤테로다당류(heteropolysaccharide)로 이루어져 결정화도가 낮고 기계적 강도와 흡착성이 떨어지지만, 반면 단세포미생물인 박테리아(bacteria)에서 생성되는 셀룰로오스의 경우 식물 셀룰로오스와는 다르게 다당류 함유량이 낮아 비교적 정제가 쉬우며 순수한 셀룰로오스를 얻을 수 있다. 따라서, 박테리아를 이용하여 추출한 셀룰로오스는 물리적 강도와 보수성, 결정화도, 흡착성, 현탁 안정성 및 결착성 등의 물리적 성질이 우수하여, 식품, 화장품 및 의약품 산업의 신소재로써 주목을 받고 있다. 특히, 박테리아 셀룰로오스의 경우 독특한 나노구조로 투과력이 높고 적합한 습도를 유지할 수 있는 등, 그 성질 때문에 습윤상태의 상처보호 및 치유에 효과가 있다고 밝혀지면서 현재 독일과 미국에서는 인조혈관(blood vessel) 및 화상환자용 인조피부(temporary skin) 등의 의료용품으로 개발되고 있는 추세이다. Cellulose (cellulose) is a major component of the cell walls of higher plants and is a rich source of biological materials in nature. Plant cellulose is composed of heteropolysaccharides mixed with polysaccharides such as pectin, hemicelluloses, and lignin, resulting in low crystallinity and low mechanical strength and adsorption. Unlike the plant cellulose, the cellulose produced in the low polysaccharide content is relatively easy to purify and obtain pure cellulose. Therefore, cellulose extracted using bacteria has attracted attention as a new material in the food, cosmetics and pharmaceutical industries because of its excellent physical properties such as physical strength, water retention, crystallinity, adsorption, suspension stability and binding properties. In particular, bacterial cellulose has been shown to be effective in protecting and healing wet wounds due to its unique nanostructure, which is highly permeable and maintains proper humidity. In Germany and the United States, blood vessels and burns are present. It is a trend that is being developed as a medical product such as artificial skin (temporary skin) for patients.

박테리아 셀룰로오스가 다양한 산업적 가능성으로 인해 주목을 받으면서 대량생산을 위한 많은 연구가 이루어졌다. 특히, 감귤이나 코코넛 등 소비는 적지만 생산량이 많은 잉여 과실류를 천연 재료 배양액으로 사용하여 박테리아 셀룰로오스를 대량생산할 경우, 환경친화적일 뿐만 아니라 고부가가치를 창출할 수 있다. 그 중에서도 감귤류는 국내의 제주도에서만 연간 60만 톤이 생산되어 생과와 감귤주스 이외의 가공품 개발에 의한 소비가 적어 대부분이 농축액 상태로 저장되거나 폐기되는 실정으로 잉여 과실류에 속하고 현재 다양한 가공품 개발이 요구되고 있다. As bacterial cellulose has attracted attention due to various industrial possibilities, much research has been done for mass production. In particular, when large quantities of bacterial cellulose are produced using surplus fruits, such as citrus fruits or coconuts, which are high in production, but with high yields, can be environmentally friendly and create high added value. Among them, citrus fruits are produced at 600,000 tons per year only in Jeju Island in Korea, and the consumption of processed products other than fresh fruit and citrus juice is low, and most of them are stored or discarded in concentrated liquid state. It is becoming.

이와 관련하여, 대한민국 등록특허 제1010055600000호 '신규한 글루콘아세토박터 속 C1 균주 및 이를 이용한 셀룰로오스 생산방법'에는 박테리아를 사용하여 셀룰로오스를 생산하는 방법이 기재되어 있으나, 이를 산업적으로 이용하는 방법에 대해서는 보고된 바가 없다.
In this regard, Republic of Korea Patent No. 1010055600000 'New Gluconacetobacter C1 strain and cellulose production method using the same' describes a method for producing cellulose using bacteria, but reports on how to use it industrially It has not been done.

1. 대한민국 등록특허 제1010055600000호 (등록일: 2010.12.27, 공개번호 제1020090129068호, 공개일: 2009.12.16)1. Republic of Korea Patent Registration No. 1010055600000 (Registration date: December 27, 2010, Publication No. 1020090129068, Publication Date: December 16, 2009)

본 발명에서는 글루콘아세토박터속 균주를 이용하여 종래에 비해 현저하게 우수한 창상 치료 효과를 갖는 셀룰로오스 겔 및 이를 함유한 드레싱 제재를 제공하고자 한다.
The present invention is to provide a cellulose gel and a dressing preparation containing the same using a gluconacetobacter strain, which has a remarkably superior wound healing effect compared to the prior art.

본 발명에서는 감귤 착즙액의 자연발효액으로부터 분리한 글루콘아세토박터 속(Gluconacetobacter sp.) KCG-2 균주를 사용하여 생성된 셀룰로오스 겔의 창상치료 용도를 제공한다. The present invention provides a wound treatment for cellulose gels produced using Gluconacetobacter sp. KCG-2 strain isolated from the natural fermentation broth of citrus juice.

또한, 본 발명에서는 상기 감귤 유래 셀룰로오스 겔을 포함하는 창상 치료용 드레싱 제재를 제공한다.In addition, the present invention provides a dressing agent for wound treatment containing the citrus-derived cellulose gel.

본 명세서에서 '창상' 이라 함은 단순히 창 , 총검 , 칼 등에 의해 다쳐서 생긴 상처만을 의미하는 것이 아니라, 절창, 찰과상, 수술 창상, 화상, 궤양, 욕창, 수술 후 감염 또는 피부염 등을 망라한 의미로 사용된다. In the present specification, the term 'wound' does not merely mean a wound injured by a spear, bayonet, knife, or the like, but is used to encompass incisions, abrasions, surgical wounds, burns, ulcers, bedsores, infections or dermatitis after surgery. do.

본 발명에서는 감귤 착즙액의 자연발효액으로부터 분리한 글루콘아세토박터 속(Gluconacetobacter sp.) KCG-326 균주를 사용하여 생성된 셀룰로오스 겔이 제공된다. The present invention provides a cellulose gel produced using Gluconacetobacter sp. KCG-326 strain isolated from the natural fermentation broth of citrus juice.

본 발명에 따른 셀룰로오스 겔은 그 자체가 드레싱 제재로 사용될 수 있을 뿐만 아니라, 붕대, 접착 붕대, 밴드, 메디폼 등의 드레싱 제재에 적용될 수도 있다.
The cellulose gel according to the present invention may not only be used as a dressing material per se, but also may be applied to dressing materials such as bandages, adhesive bandages, bands, and mediforms.

일반적으로 창상의 치유 과정이 저해되면 창상은 만성 창상으로 발전하게 되고, 이러한 만성 창상은 치유가 어려우며 수술적 치료를 요하는 경우가 많다. 본 발명에 따른 감귤 유래 박테리아 셀룰로오스는 초기 염증 반응을 줄이고 세포외기질의 축적을 통한 수축 반응을 촉진시켜 창상 치유에 효과적이며, 상기 감귤 유래 박테리아 셀룰로오스를 이용한 드래싱 제재는 효과적인 창상치유제로 사용가능하다.
In general, when the healing process of the wound is inhibited, the wound develops into a chronic wound, and the chronic wound is difficult to heal and often requires surgical treatment. Citrus-derived bacterial cellulose according to the present invention is effective in wound healing by reducing the initial inflammatory response and promoting the contractile reaction through the accumulation of extracellular matrix, and the dressing agent using the citrus-derived bacterial cellulose can be used as an effective wound healing agent.

도 1은 감귤 셀룰로오스 겔의 배양 7일째 사진이다.
도 2는 정제 과정을 거친 백색 셀룰로오스 겔을 나타낸 사진이다.
도 3에서 A는 스프래그-둘리(Sprague-Dawley)종 백서 등 위의 3곳에 지름 2cm 원형의 피부전층 창상을 낸 사진이고, B는 드레싱 제재인 바셀린 거즈(a), 알지네이트 디스크(b), 본 발명에 따른 셀룰로오스 겔 각각을 적용한 사진이고, C는 ‘Peha-haft(등록상표)을 두르고 나이론 4-0으로 봉합한 사진이다.
도 4는 피부전층 절개를 시술한 후 3, 6, 9, 12, 15, 18, 21, 24 및 28일째 창상 반흔의 사진이다.
도 5는 본 발명에 따른 셀룰로오스 겔 처리군 및 바셀린 거즈 처리군의 창상 면적을 나타낸 그래프로, 각각의 막대는 3회의 별도 실험의 평균값±S.E.(n=3)을 나타내고, p<0.05가 바셀린 거즈 처리군과 유의한 차이를 갖는 것으로 간주된다.
도 6은 시술 7일 후 바셀린 거즈 처리군(좌측), Algisite M(등록상표) 처리군(중앙), 본 발명에 따른 셀룰로오스 겔 처리군(우측)을 헤마톡실린- 에오진으로 염색한 조직 결과를 나타낸 사진이다.
도 7은 시술 14일 후 바셀린 거즈 처리군(상단, 좌측), Algisite M(등록상표) 처리군(상단, 중앙), 본 발명에 따른 셀룰로오스 겔 처리군(상단, 우측)을 헤마톡실린- 에오진으로 염색한 조직 결과를 100배 확대한 사진이고, 그 아래에는 각각을 200배 확대한 사진이다.
도 8은 창상 7일, 14일 및 21일 경과후에 바셀린 거즈 처리군(A), 알지네이트 디스크 처리군(B), 본 발명에 따른 셀룰로오스 겔 처리군(C)의 창상 피부 TGF-β및 VEGF 단백질 발현을 나타낸 사진이고, 여기서 액틴은 비교대조군으로 사용되었다.
1 is a photograph of the seventh day culture of citrus cellulose gel.
Figure 2 is a photograph showing a white cellulose gel after a purification process.
In Figure 3, A is a photo of the skin layer wound of 2 cm in diameter on three places including Sprague-Dawley species white paper, B is a vaseline gauze (a), alginate disk (b), a dressing material, Each of the cellulose gels according to the present invention is applied to photographs, and C is a photograph covered with 'Peha-haft® and sealed with nylon 4-0.
Figure 4 is a photograph of wound scars at 3, 6, 9, 12, 15, 18, 21, 24 and 28 days after the skin layer incision.
Figure 5 is a graph showing the wound area of the cellulose gel treatment group and petrolatum gauze treatment group according to the present invention, each bar represents the average value ± SE (n = 3) of three separate experiments, p <0.05 is petrolatum gauze It is considered to have a significant difference from the treatment group.
6 is a tissue result of staining the petrolatum gauze treatment group (left), Algisite M (registered trademark) treatment group (center) and the cellulose gel treatment group (right) according to the present invention 7 days after the procedure. Is a picture showing.
7 shows hematoxylin-eo in petrolatum gauze treatment group (top, left), Algisite M (registered trademark) treatment group (top, middle), cellulose gel treatment group (top, right) according to the present invention 14 days after the procedure. The result of the tissue stained with jeans is magnified 100 times, and below each is 200 times magnified.
Fig. 8 shows wound skin TGF-β and VEGF proteins of the petrolatum gauze treatment group (A), the alginate disc treatment group (B), and the cellulose gel treatment group (C) according to the present invention after 7 days, 14 days and 21 days after the wound. It is a photograph showing the expression, where actin was used as a control.

본 발명은 하기 실시예에 의해 보다 구체적으로 설명되지만, 하기 실시예는 단지 예시를 목적으로 한 것이며, 본 발명의 권리범위가 이에 한정되지 않음이 당업자들에게 명백히 이해될 것이다.
Although the present invention is described in more detail by the following examples, the following examples are for illustrative purposes only and it will be apparent to those skilled in the art that the scope of the present invention is not limited thereto.

실험 재료Experimental material

실험동물로는 체중 200g - 250g의 스프래그-둘리(Sprague-Dawley)종 수컷 백서를 사용하였다. 실험 동물은 온도 24 ± 0.5 ℃, 습도 55 - 65% 및 12시간 주기로 명암이 자동으로 조절되는 사육조건 하에서 관리되었으며, 약 14일간 환경에 적응시킨 후 실험에 사용하였다.
Sprague-Dawley male white papers weighing 200g-250g were used as experimental animals. The experimental animals were kept under a breeding condition in which the contrast was automatically controlled at a temperature of 24 ± 0.5 ° C., a humidity of 55-65% and a 12 hour period, and used for experiments after adapting to the environment for about 14 days.

제조예Manufacturing example 1: 감귤 유래 박테리아 셀룰로오스  1: Citrus-derived Bacteria Cellulose 겔의Gel 정제 및 제작 Refining and fabrication

셀룰로오스 겔을 제조하는데 사용되는 글루콘아세토박터 속(Gluconacetobacter sp.) gel_KCG326 균주는 감귤착즙액으로부터 분리된 신균주로서, 농업유전자원정보센터 미생물은행에 2010년 5월 11일자로 기탁된 것이다(기탁 번호 : KACC 91555P). Gluconacetobacter sp. Gel_KCG326 strain, which is used to prepare cellulose gel, is a new strain isolated from citrus juice, and was deposited on May 11, 2010 to the Microbial Bank of Agricultural Genetic Resource Information Center. Number: KACC 91555P).

겔 발효용 배지에 사용되는 감귤 농축액으로는 국립원예특작과학원 감귤 시험장에서 착즙한 평균당도 85 °Brix의 서귀포산 온주밀감 농축액을 -20℃에서 저장하였으며 해동 후 사용하였다. As a citrus concentrate used in the medium for gel fermentation, Seogwipo acid Wenju citrus concentrate with an average sugar content of 85 ° Brix was stored at -20 ° C and used after thawing.

겔 발효용 배지로는 시판 당액 9%, 상기 감귤농축액 1%(v/v), 에탄올 1%(v/v) 및 아세트산 1%(v/v)을 첨가하여 발효용 감귤과즙배지에 상기 글루콘아세토박터(Gluconacetobacter sp.) 속 gel_KCG326 균주를 수회 반복 배양한 후 배지 표면에 형성된 겔을 종균으로 사용하였다. 배지를 50 mL 용적의 발효병에 35 mL씩 분주하고 전 배양한 겔 5%(W/V)을 접종한 후 발효병 입구를 살균된 여과지로 덮고 28의 배양실에서 7일간 정치 배양하였다. 그 결과, 배양 2일부터 겔 막이 형성되기 시작하여 7일 경과 후 생성된 감귤 셀룰로오스 겔을 도 1에 나타내었다.
As the gel fermentation medium, 9% of the commercial sugar solution, 1% (v / v) of the citrus concentrate, 1% (v / v) of ethanol, and 1% (v / v) of acetic acid were added to the citrus fruit juice medium for fermentation. After repeatedly culturing the gel_KCG326 strain of Gluconacetobacter sp. In the Gluconacetobacter sp., The gel formed on the surface of the medium was used as a seed. The medium was divided into 50 mL volumes of fermentation bottles by 35 mL, inoculated with 5% (W / V) of pre-incubated gel, and then the inlet of the fermentation bottles was covered with sterile filter paper and left incubated in 28 culture chambers for 7 days. As a result, the gel film was formed from the second day of culture, and the resulting citrus cellulose gel 7 days later is shown in FIG. 1.

제조예 2: 감귤 유래 박테리아 셀룰로오스 겔의 정제Preparation Example 2 Purification of Citrus-derived Bacteria Cellulose Gel

제조예 1에서 배양된 셀룰로오스 겔의 정제는 감귤겔에 0.1N NaOH와 0.1N HCl로 반복 처리하여 색소와 불순물을 제거한 후 40 ℃ dry oven에서 건조하면서 드레싱(dressing)하기 적당할 정도로 수분을 제거하여 압착 후 15분간 가압·살균하였다. 그 결과 색소, 불순물 및 수분이 제거되어 드레싱하기 적당한 백색 셀룰로오스 겔(두께 2mm, 지름 26mm)을 얻을 수 있었다(도 2).
Purification of the cellulose gel cultured in Preparation Example 1 was repeatedly treated with citrus gel 0.1N NaOH and 0.1N HCl to remove the pigment and impurities, and then dried in a 40 ℃ dry oven to remove moisture to the extent that it is suitable for dressing (dressing) After pressing, the mixture was pressurized and sterilized for 15 minutes. As a result, a white cellulose gel (thickness 2mm, diameter 26mm) suitable for dressing by removing the pigment, impurities and water was obtained (Fig. 2).

실험예Experimental Example

(1) 실험 준비(1) Preparation for Experiment

본 발명에 따른 감귤 유래 박테리아 셀룰로오스 겔의 창상치유 효과를 알아보기 위해서 백서 등에 직경 2 cm의 원형의 피부전층창상을 3곳 만들고 각 창상에 적용한 드레싱 재료에 따라서 A, B, C 처리군으로 세분한 실험군을 준비하였다.In order to investigate the wound healing effect of the citrus-derived bacterial cellulose gel according to the present invention, three round skin skin wounds having a diameter of 2 cm were made on white paper, and subdivided into A, B, C treatment groups according to the dressing material applied to each wound. The experimental group was prepared.

A 처리군에는 바셀린 거즈를 사용하였는데, 바셀린 거즈는 고식적인 드레싱 재료를 대표하는 물질로서 선택하였는데, 창상을 습윤하게 유지시켜 주지만 성장인자나, 항염증작용을 돕는 성분이 없으므로 대조군으로 사용하였다.Vaseline gauze was used for the A-treated group. Vaseline gauze was selected as a representative material of the conventional dressing material, but it was used as a control because it keeps the wound wet but there is no growth factor or an ingredient that helps anti-inflammatory action.

B 처리군에는 창상 치유효과가 알려진 Algisite M (등록상표)부직포(Smith & nephew, USA)를 사용하였다.In the treatment group B, Algisite M® nonwoven fabric (Smith & nephew, USA), which is known for its wound healing effect, was used.

C 처리군에는 상기 제조예에서 제조된 감귤 유래 박테리아 셀룰로오스 겔을 사용하였다.
In the C treatment group, the tangerine-derived bacterial cellulose gel prepared in the preparation example was used. Respectively.

(2) 실험 과정(2) experimental process

국소치료제의 창상치유효과 측정시 전층피부 결손 모델이 부분층피부 결손 모델보다 적합하다는 보고를 참고하여 실험을 진행하였다[Reimer, K., et al., Antimicrobial effectiveness of povidone-iodine and consequences for new application areas. Dermatology, 2002. 204 Suppl 1: p. 114-20.]. Experiments were conducted with reference to reports that the delamination model was more suitable than the delamination model for measuring wound healing effects of topical treatments [Reimer, K., et al., Antimicrobial effectiveness of povidone-iodine and consequences for new application. areas . Dermatology, 2002. 204 Suppl 1: p. 114-20.].

20 마리의 백서 등에 지름 2 cm 원형의 피부전층창상을 3곳에 만들어 각각의 창상에 3가지 드레싱 재료를 무작위로 할당하였다(도 3 참조). 실험동물은 수술 후 3, 7, 14, 21, 28일에 각 4 마리를 희생하여 피부조직을 채취하였다. 수술 시에는 졸레틸 50(Virbac, Frances)을 근육 주사하여 마취하였고, 백서 등의 털을 면도한 후 베타딘과 알콜로 소독하고 15번 칼과 조직가위를 이용하여 3곳에 동일한 크기(지름 2 cm의 원형창상)와 동일한 깊이 (표피구조를 보정하는 표층근막(superficial fascia)인 육상층(panniculus carnosus)을 보존하는 수준)의 피부전층창상을 만들었다. 모든 처리군에서 수술 후 7일까지는 이틀에 한번씩, 8일부터 그 후 까지는 3 - 4일에 한번씩 드레싱 하였다.
Twenty white papers were made with three cutaneous cuticles of 2 cm diameter on each skin, and three dressing materials were randomly assigned to each wound (see FIG. 3). Experimental animals harvested skin tissue at the expense of four animals at 3, 7, 14, 21, and 28 days after surgery. At the time of surgery, anesthetized by intramuscular injection of zoletil 50 (Virbac, Frances), shaved the hair of white paper, disinfected with betadine and alcohol, and using the knife No. 15 and tissue scissors at the same size (2 cm in diameter). Epidermal wounds of the same depth (preservation of the panniculus carnosus, a superficial fascia that corrects the epidermal structure). In all treatment groups, dressings were done every other day until 7 days after surgery and once every 3-4 days from 8 days thereafter.

(3) 실험 평가(3) experimental evaluation

1) 육안적 평가1) Visual Evaluation

피부전층창상을 만든 후 창상의 테두리를 멸균 처리한 투명 OHP 필름에 따라 그리고 스캔하여 그 면적을 영상 분석 프로그램인 (NIH image analysis system, Bio-Optics사, USA)를 이용하여 창상의 면적을 측정하였다. 피부전층창상 시술 후 3일마다 수술 시와 동일한 방법으로 백서를 마취시키고 창상의 면적을 측정하였다. 구한 값을 토대로 창상유발 1일째 면적을 100%로 하고 백분율로 환산하여 면적의 변화를 비교하여 구하였다. After the skin layer was made, the area of the wound was measured using a transparent OHP film sterilized and scanned and the area was measured using an image analysis program (NIH image analysis system, Bio-Optics, USA). . White skin was anesthetized and the area of the wound was measured every three days after the epidermal wound procedure. On the basis of the obtained values, the area was determined to be 100% on the first day of wound induction, and the change in area was compared.

그 결과, 도 4로부터 알 수 있듯이, 창상 후 6일 동안은 창상 부위에서 다량의 삼출물이 배출되었는데 본 발명에 따른 셀룰로오스 겔을 드레싱한 처리군에서의 삼출물 배출량은 대조군인 바셀린 거즈 처리군보다는 빠르게 감소하였고, 창상 치유에 효과가 있다고 알려진 Algisite M(등록상표) 처리군과는 비슷한 수준이었다. 창상 면적은 창상 치유기간 동안 서서히 감소하여 수술 후 18일에서 28일 사이에 대부분의 창상이 치유되었다.As a result, as can be seen from Figure 4, a large amount of exudate was discharged from the wound site for 6 days after the wound, the exudate discharge rate in the treatment group dressing the cellulose gel according to the present invention decreases faster than the control group Vaseline gauze treatment group It was similar to the Algisite M® treatment group, which is known to be effective in wound healing. The wound area gradually decreased during the wound healing period, and most wounds healed between 18 and 28 days after surgery.

또한, 최초 창상면적을 100%로 하여 시간 경과에 따른 창상면적 감소를 백분율로 나타낸 그래프를 도 5에 도시하였다. 그 결과, 수술 후 6일부터 바셀린 거즈 처리군(대조군, 67.6%), Algisite M (등록상표) 처리군(60.4%) 및 본 발명에 따른 셀룰로오스 겔 처리군(64.3%)에서 처리군 간의 차이는 보이지 않았지만 모든 군에서 유의적으로 창상면적이 감소하였다. 수술 후 9일 전후부터 처리군 간의 차이가 나타나기 시작하였다. 대조군의 경우 창상면적이 수술 후 9일째 50.2% 이었으나, 본 발명에 따른 셀룰로오스 겔 처리군의 경우에는 37.5%로 통계학적으로 차이를 보였으며, 창상치유 효과가 있다고 입증된 Algisite M (등록상표) 처리군(37.6%)과 비슷한 수치를 보였다. 또한, 수술 후 15일째에는 대조군, Algisite M (등록상표) 처리군 및 감귤 유래 박테리아 셀룰로오스 겔 처리군에서 창상면적이 각각 33.0%, 14.5% 및 7.2%로 큰 차이의 통계학적 유의성(P<0.05)이 나타났다.
In addition, a graph showing the percentage of wound area decrease over time as a percentage with the initial wound area as 100% is shown in FIG. 5. As a result, the difference between the treated group in the petrolatum treated group (control group, 67.6%), Algisite M (registered trademark) treated group (60.4%) and cellulose gel treated group (64.3%) according to the present invention from 6 days after surgery Although not seen, the wound area was significantly reduced in all groups. Differences between treatment groups began to appear around 9 days after surgery. In the control group, the wound area was 50.2% on the 9th day after surgery, but in the cellulose gel treatment group according to the present invention, the difference was statistically 37.5%, and Algisite M (Trademark) treatment, which was proved to have a wound healing effect, was used. The figure was similar to that of the group (37.6%). On the 15th day after surgery, the wound area was 33.0%, 14.5% and 7.2% in the control group, Algisite M® group and citrus-derived bacterial cellulose gel group, respectively ( P <0.05). Appeared.

2) 조직학적 관찰2) Histological observation

조직학적인 평가를 위하여 백서에 창상을 만든 후 3, 7, 10, 14, 21일째에 전체 창상을 적출하여 즉시 10% 포르말린에 고정하고 파라핀에 포매한 후 6 ㎛ 두께로 잘라 헤마톡실린-에오진 (Hematoxylin-Eosin)으로 염색하여 관찰하였다. 각 사용물질들의 시간에 따른 창상치유 효과는 크게 네 가지 항목으로 나누어 관찰하였는데 재상피화, 섬유모세포의 증식, 다핵구와 림프구의 침윤 그리고 혈관생성의 정도를 관찰하였다.Wounds were made on white paper for histological evaluation, and then the entire wounds were removed on days 3, 7, 10, 14 and 21, immediately fixed in 10% formalin, embedded in paraffin, and cut into 6 μm thick hematoxylin-eozin. It was observed by staining with (Hematoxylin-Eosin). The effects of wound healing over time on each material were divided into four categories: re-epithelialization, fibroblast proliferation, multinucleated and lymphocyte infiltration, and angiogenesis.

수술후 3일 째 모든 처리군에서 중성구의 침윤이 관찰되었으며 수술후 7일째 모든 처리군에서 중성구의 침윤이 증가하였으나 바셀린 거즈 처리군이 Algisite M (등록상표) 처리군과 본 발명에 따른 셀룰로오스 겔 처리군보다 중성구의 수가 많이 관찰되었다(도 6 참조). 또한, 근섬유모세포의 출현이 모든 처리군에서 관찰되었으나 Algisite M(등록상표) 처리군과 본 발명에 따른 셀룰로오스 겔 처리군에서 바셀린 거즈 처리군보다 많은 수의 근섬유모세포의 수가 관찰되었다. 수술후 14일째 모든 군에서 창상의 상피화가 진행된 것이 관찰되었으며 Algisite M (등록상표) 처리군과 본 발명에 따른 셀룰로오스 겔 디스크 처리군에서 바셀린 거즈 처리군보다 콜라겐 축적 정도가 많았으며 신생 혈관의 수도 많이 관찰되었다(도 7 참조). 하지만, 수술후 14일째 관찰되는 신생혈관의 수는 수술후 7일째보다 적게 관찰되었다.
On day 3 postoperatively, neutrophil infiltration was observed in all treatment groups and on day 7 postoperatively, neutrophil infiltration was increased in all treatment groups, but the petrolatum gauze treatment group was more effective than Algisite M® treatment group and cellulose gel treatment group according to the present invention. A large number of neutrophils were observed (see FIG. 6). In addition, the appearance of myofibroblasts was observed in all treatment groups, but the number of myofibroblasts in the Algisite M® treatment group and the cellulose gel treatment group according to the present invention was higher than that of the petrolatum gauze treatment group. Wound epithelialization was observed in all groups on day 14 postoperatively. Algisite M® and cellulose gel disc treatment groups according to the present invention had higher levels of collagen accumulation than petrolatum gauze treatment group, and the number of new blood vessels was observed. (See FIG. 7). However, the number of neovascularizations observed on day 14 postoperatively was less than on day 7 postoperatively.

3) 단백질 분석3) Protein Analysis

조직의 재생과 세포분화에서 중요한 역할을 하는 TGF-β와 혈관신생에 관여하는 VEGF에 대한 단백질 분석을 시행하였다. 조직을 lysis buffer solution(iNtRON biotechnology, Korea)에 넣고 조직분쇄기로 분쇄한 후 얼음 위에서 30분간 반응시키고 30분간 원심분리(4℃, 12,000 rpm)하여 단백질을 추출하였다. 단백질 농도는 iNtRON biotechnology Protein assay kit를 사용하여 정량하고, 50mg의 단백질을 12%의 SDS-PAGE(poly acrylamide gel electrophoresis)로 변성 분리한 후 니트로셀룰로오스 막(nitrocellulose membrane)(Amersham, Netherlands)으로 전이시켜, 5% 탈지유(skim milk)가 함유된 TBS 용액으로 상온에서 1시간 동안 블로킹(blocking)하였다. 단백질 발현정도를 측정하기 위하여 TBS에 희석(1 : 1000)시킨 1차 항체 형질전환증식인자(transforming growth factor:TGF)-β, 혈관 내피세포 증식 인자(Vascular endothelial growth factor:VEGF) (Santa Cruz, U.S.A.)를 상온에서 2시간 동안 반응시킨 후 3회 세척하였다. 2차 항체는 anti-rabbit IgG, anti-mouse IgG (Santa Cruz, U.S.A.)를 1 : 2000으로 희석하여 상온에서 1시간 동안 반응시킨 후 5회 세척하여 ECL (Thermo, Japan)과 반응 후 감광하여 발현 정도를 확인하였다.Protein analysis was performed for TGF-β, which plays an important role in tissue regeneration and cell differentiation, and for VEGF, which is involved in angiogenesis. The tissue was placed in lysis buffer solution (iNtRON biotechnology, Korea), crushed with a tissue crusher, reacted on ice for 30 minutes, and centrifuged for 30 minutes (4 ° C., 12,000 rpm) to extract proteins. Protein concentration was quantified using the iNtRON biotechnology Protein assay kit, 50 mg of protein was denatured with 12% poly acrylamide gel electrophoresis (SDS-PAGE) and transferred to a nitrocellulose membrane (Amersham, Netherlands). , Blocking with TBS solution containing 5% skim milk at room temperature for 1 hour. Primary antibody transforming growth factor (TGF) -β, Vascular endothelial growth factor (VEGF) diluted in TBS (1: 1000) to measure protein expression (Santa Cruz, USA) was reacted at room temperature for 2 hours and then washed three times. Secondary antibodies are diluted 1: 2000 with anti-rabbit IgG, anti-mouse IgG (Santa Cruz, USA), reacted at room temperature for 1 hour, washed 5 times, and then reacted with ECL (Thermo, Japan) for photosensitization. The degree was confirmed.

백서의 창상모델에서 일수 별로 적출한 창상조직은 -70℃에서 보관하였으며 단백질을 분리한 후 조직재생과 세포분화에 관여하는 중요 성장인자인 TGF-β1과 혈관 생성에 영향을 주는 VEGF의 단백질 발현량을 웨스턴 블롯팅(Western blotting)으로 분석하였다(도 8 참조). TGF-β1의 경우 수술 후 7일에는 모든 군에서 비슷한 수준으로 발현이 일어났으나, 수술 후 14일 그리고 21일에서는 대조군에서만 발현되고 Algisite M (등록상표) 처리군과 본 발명에 따른 셀룰로오스 처리군에서는 차차 감소되는 것으로 나타났다. VEGF의 경우에는 수술 후 7일에 감귤 유래 박테리아 셀룰로오스 처리군에서 가장 높게, 대조군에서는 가장 낮게 발현 되었으나, 14일 후부터는 TGF-β1과 같은 양상으로 대조군에서 높게 발현되고 Algisite M(등록상표) 처리군과 감귤 유래 박테리아 셀룰로오스 처리군에서는 차차 감소되는 것으로 나타났다. 이는 도 4 및 도 5에서 보여지듯이 창상치유가 가장 활발했던 수술 후 7일에서 성장인자의 발현이 높게 나타났고, 창상이 거의 치유되었던 14일에서는 그 발현량이 낮아지는 것을 확인했다. 반면, 대조군에서는 수술 후 12일에도 40% 이상의 창상이 치유되지 못하였고, Algisite M(등록상표) 처리군과 감귤 유래 박테리아 셀룰로오스 처리군에 비하여 창상치유 속도가 느려서 14일과 21일에서도 성장인자가 다른 군에 비하여 높게 발현되는 것으로 나타났다.The wound tissues extracted by the number of days in the wound model of the white paper were stored at -70 ℃, and the protein expression level of TGF-β1, an important growth factor involved in tissue regeneration and cell differentiation and VEGF, which influences angiogenesis after protein isolation Were analyzed by Western blotting (see FIG. 8). In the case of TGF-β1, the expression level was similar in all groups on the 7th day after surgery, but on the 14th and 21st day after the surgery, it was expressed only in the control group and treated with Algisite M® and the cellulose treatment group according to the present invention. Gradually decreased. VEGF was highest in citrus-derived bacterial cellulose treatment group and lowest in control group at 7 days after surgery, but after 14 days, it was expressed in TGF-β1 and high in control group and treated with Algisite M® treatment group. In the citrus-derived bacterial cellulose treatment group, it was gradually decreased. As shown in FIGS. 4 and 5, the growth factor expression was high at 7 days after the surgery when the wound healing was most active, and the expression level was lowered at 14 days when the wound was almost cured. On the other hand, the control group did not heal more than 40% of the wounds on the 12th day after surgery, and compared with the Algisite M® group and the citrus-derived bacterial cellulose group, the wound healing rate was slower. It was expressed higher than the group.

국립농업과학원 농업유전자원센터National Institute of Agricultural Science KACC91555KACC91555 2010051120100511

Claims (3)

글루콘아세토박터속 균주를 이용하여 감귤로부터 추출된 것을 특징으로 하는 창상치료용 셀룰로오스 겔.Cellulose gel for wound treatment, characterized in that extracted from the tangerine using a gluconacetobacter strain. 제1항의 셀룰로오스 겔이 유효성분으로 적용된 것을 특징으로 하는 창상치료용 드레싱 제재.The dressing agent for wound treatment, wherein the cellulose gel of claim 1 is applied as an active ingredient. 제2항에 있어서, 하이드로콜로이드 또는 습윤 폼 형태인 것을 특징으로 하는 창상치료용 드레싱 제재.
The dressing agent for wound treatment according to claim 2, which is in the form of a hydrocolloid or a wet foam.
KR1020110117794A 2011-11-11 2011-11-11 Bacterial synthesized citrus cellolose for wound healing and dressing materials containing the same KR101365065B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020110117794A KR101365065B1 (en) 2011-11-11 2011-11-11 Bacterial synthesized citrus cellolose for wound healing and dressing materials containing the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020110117794A KR101365065B1 (en) 2011-11-11 2011-11-11 Bacterial synthesized citrus cellolose for wound healing and dressing materials containing the same

Publications (2)

Publication Number Publication Date
KR20130052386A true KR20130052386A (en) 2013-05-22
KR101365065B1 KR101365065B1 (en) 2014-02-20

Family

ID=48662017

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020110117794A KR101365065B1 (en) 2011-11-11 2011-11-11 Bacterial synthesized citrus cellolose for wound healing and dressing materials containing the same

Country Status (1)

Country Link
KR (1) KR101365065B1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101522592B1 (en) * 2013-06-27 2015-05-26 대한민국 Method for manufacturing cellulose gel using remnants after extraction of Citrus
CN108066814A (en) * 2017-12-11 2018-05-25 常州市协旺纺织品有限公司 A kind of preparation method of bacteria cellulose antiseptic dressing
KR20220088209A (en) * 2020-12-18 2022-06-27 대한민국(농촌진흥청장) A composition for preventing or treating inflammatory disease comprising extract of C. hassaku Hort. ex Y. Tan and Rehmanniae Radix preparata as effective component

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101522592B1 (en) * 2013-06-27 2015-05-26 대한민국 Method for manufacturing cellulose gel using remnants after extraction of Citrus
CN108066814A (en) * 2017-12-11 2018-05-25 常州市协旺纺织品有限公司 A kind of preparation method of bacteria cellulose antiseptic dressing
KR20220088209A (en) * 2020-12-18 2022-06-27 대한민국(농촌진흥청장) A composition for preventing or treating inflammatory disease comprising extract of C. hassaku Hort. ex Y. Tan and Rehmanniae Radix preparata as effective component

Also Published As

Publication number Publication date
KR101365065B1 (en) 2014-02-20

Similar Documents

Publication Publication Date Title
Mir et al. Synthetic polymeric biomaterials for wound healing: a review
Gaspar-Pintiliescu et al. Natural composite dressings based on collagen, gelatin and plant bioactive compounds for wound healing: A review
Moraes et al. Bacterial cellulose/collagen hydrogel for wound healing
Wang et al. The effect of form of carboxymethyl-chitosan dressings on biological properties in wound healing
JP2834155B2 (en) Collagen flake body
WO2019091150A1 (en) Alginate wound repair dressing and preparation method thereof
Cui et al. Collagen-tussah silk fibroin hybrid scaffolds loaded with bone mesenchymal stem cells promote skin wound repair in rats
Han et al. Antioxidant and multi-sensitive PNIPAAm/keratin double network gels for self-stripping wound dressing application
KR20130119674A (en) A composition comprising alginate with fibroblast growth factor for wound healing
CN109776819B (en) Bletilla striata polysaccharide-carboxymethyl chitosan composite hydrogel and preparation thereof
Coriolano et al. Parkia pendula seed lectin: potential use to treat cutaneous wounds in healthy and immunocompromised mice
ES2467668T3 (en) Pharmaceutical composition, bandage and method to treat skin lesion, intermediate composition and process to prepare said bandage and use of cerium salt associated with a collagen matrix
KR101365065B1 (en) Bacterial synthesized citrus cellolose for wound healing and dressing materials containing the same
Rathinamoorthy et al. In vivo–Wound healing studies of Leptospermum scoparium honey loaded chitosan bioactive wound dressing
Thomas A review of the physical, biological and clinical properties of a bacterial cellulose wound
US11400120B2 (en) Composition comprising collagen and honey
CN104474573A (en) Biological mask and preparation method thereof
RU2370270C1 (en) Composition for wound treatment
RU2372922C1 (en) Therapy of deep burn of skin
US20150328268A1 (en) Marine Plants Extract for Wound Healing
CN114225113B (en) Degradable artificial dura mater with double-layer structure and preparation method thereof
CN115177778A (en) Composite wound dressing, preparation method and application
TW201323021A (en) A biocellulose dressing, and the preparation process and uses thereof
Sanjarnia et al. Bringing innovative wound care polymer materials to the market: Challenges, developments, and new trends
CN113648456A (en) Preparation method of eel swimming bladder collagen-chitosan-composite sodium alginate hydrogel

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20170210

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20180209

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20190211

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20200210

Year of fee payment: 7